<p>Avadel 制药公司（NASDAQ:AVDL）在 6 月份的空头头寸大幅增加。截至 6 月 15 日，空头头寸总计为 720 万股，比 5 月 31 日的 648 万股增加了 11.1%。根据平均交易量为 100 万股，目前的偿付日比率为 7.2 天。</p>
<p>获取 <strong>Avadel 制药</strong> 的警报：</p>
<h2>Avadel 制药的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近调整了他们对 AVDL 的持股。Chilton Capital Management LLC 在第一季度购入了价值 51000 美元的 Avadel 制药股票。BNP Paribas Financial Markets 在第一季度增持了 Avadel 制药的股票，持股增长了 60.5%。BNP Paribas Financial Markets 现在拥有 4469 股该公司股票，价值 75000 美元，比上一季度增持 1685 股。Quarry LP 在第四季度购入了价值约 12 万美元的 Avadel 制药股票。Claro Advisors LLC 在第一季度购入了价值约 17.2 万美元的 Avadel 制药股票。最后，中国通用资产管理有限公司在第四季度将其对 Avadel 制药的持仓增加了 349.4%。中国通用资产管理有限公司现在拥有 10327 股该公司股票，价值 146000 美元，在该时期内增持了 8029 股。机构投资者拥有该公司股票的 69.19%。</p>
<h2>华尔街分析师的观点</h2>
<p>一些研究公司最近对 AVDL 发表了意见。Rodman \u0026 Renshaw 在 6 月 12 日星期三的研究报告中对 Avadel 制药的股票进行了覆盖。他们给出了一项&#34;买入&#34;评级，并将股票的目标价定为 27.00 美元。Craig Hallum 将 Avadel 制药的目标价从 22.00 美元上调至 23.00 美元，并在 5 月 9 日星期四的研究报告中给予该股票&#34;买入&#34;评级。Needham \u0026 Company LLC 在 5 月 8 日星期三的研究报告中重申了对 Avadel 制药的&#34;买入&#34;评级，并将目标价定为 22.00 美元。HC Wainwright 将 Avadel 制药的目标价从 25.00 美元上调至 27.00 美元，并在 5 月 9 日星期四的报告中给予该股票&#34;买入&#34;评级。最后，Oppenheimer 将 Avadel 制药的目标价从 27.00 美元上调至 29.00 美元，并在 3 月 5 日星期二的研究报告中给予该公司&#34;表现优异&#34;评级。根据 MarketBeat.com 的数据，七位股票研究分析师对该股票给出了买入评级，Avadel 制药目前的平均评级为&#34;买入&#34;，共识目标价为 24.57 美元。</p>
<p><strong>查看我们对 Avadel 制药的最新股票报告</strong></p>
<h2>Avadel 制药股价下跌 1.7%</h2>
<p>周一，Avadel 制药股票开盘价为 14.06 美元。该公司的 50 天简单移动平均线为 16.12 美元，200 天简单移动平均线为 15.43 美元。Avadel 制药的 12 个月最低价为 9.50 美元，最高价为 19.09 美元。该公司的市值为 13.5 亿美元，市盈率为-7.56，贝塔系数为 1.53。</p>
<p>Avadel 制药（NASDAQ:AVDL）于 5 月 8 日发布了季度财报。公司报告的每股收益为-0.30 美元，低于分析师预期的-0.25 美元。Avadel 制药的净利润率为-284.42%，净资产收益率为-139.72%。该季度公司的营收为 2718 万美元，超过分析师对 2589 万美元的预期。与去年同期相比，公司的季度营收同比增长 2617.8%。作为一个群体，股票研究分析师预计，Avadel 制药本财年的每股收益将为-0.58 美元。</p>
<h2>关于 Avadel 制药（获取免费报告）</h2>
<p>Avadel 制药公司是一家在美国运营的生物制药公司。其主要产品候选药物是 LUMRYZ，一种盐酸奥沙巴汀的制剂，目前正在进行用于治疗成年人的过度日间嗜睡或猝倒的第 3 期临床试验。该公司以前被称为 Flamel Technologies SA，于 2017 年 1 月更名为 Avadel 制药公司。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票比 Avadel 制药更好</li>
<li>3 家可以帮助抵御通货膨胀的杂货股</li>
<li>分析师升级的 3 只股票：家得宝、美国钢铁、美国铝业</li>
<li>内部人士出售解释：它能指导您的投资选择吗？</li>
<li>NVIDIA 和 TSM 股票：半导体行业的势头是否减缓？</li>
<li>什么是标准普尔 500 指数及其与其他指数的区别</li>
<li>Palo Alto Networks 股票获得基于人工智能的网络安全解决方案的增益</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
<p>→ Jeff Bezos 和 48 名国会议员正在购买一个行业...（来自 InvestorPlace）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTE1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTE1"/></p>
<h2>您现在是否应该投资 1000 美元购买 Avadel 制药？</h2>
<p>在考虑 Avadel 制药之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在应该购买的股票...而 Avadel 制药不在这份名单上。</p>
<p>尽管 Avadel 制药目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票是更好的选择。</p>
<p>查看这五只股票</p>

Avadel制药

<p>Avadel 制药（NASDAQ:AVDL）在 6 月份空头头寸增加了 11.1%，达到了 7,200,000 股。目前的偿付日比率为 7.2 天。几家机构投资者已经调整了他们对 AVDL 的持股。华尔街分析师给予该股票 “买入” 评级，目标股价为 24.57 美元。Avadel 制药的股价开盘为 14.06 美元，市值为 13.5 亿美元。该公司上个季度报告显示净利润率和净资产收益率为负数</p>

<p>Avadel Pharmaceuticals plc (NASDAQ:AVDL - Get Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 7,200,000 shares, an increase of 11.1% from the May 31st total of 6,480,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is presently 7.2 days.</p>
<div class="lb-trans"><p>Avadel 制药公司（NASDAQ:AVDL）在 6 月份的空头头寸大幅增加。截至 6 月 15 日，空头头寸总计为 720 万股，比 5 月 31 日的 648 万股增加了 11.1%。根据平均交易量为 100 万股，目前的偿付日比率为 7.2 天。</p>
</div><p>Get <strong>Avadel Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avadel 制药</strong> 的警报：</p>
</div><h2>Institutional Trading of Avadel Pharmaceuticals</h2>
<div class="lb-trans"><h2>Avadel 制药的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of AVDL. Chilton Capital Management LLC bought a new position in shares of Avadel Pharmaceuticals in the first quarter worth $51,000. BNP Paribas Financial Markets grew its holdings in Avadel Pharmaceuticals by 60.5% during the 1st quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company's stock valued at $75,000 after buying an additional 1,685 shares in the last quarter. Quarry LP bought a new stake in shares of Avadel Pharmaceuticals during the fourth quarter valued at about $120,000. Claro Advisors LLC purchased a new stake in shares of Avadel Pharmaceuticals in the first quarter worth about $172,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Avadel Pharmaceuticals by 349.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,327 shares of the company's stock valued at $146,000 after acquiring an additional 8,029 shares during the period. Institutional investors own 69.19% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了他们对 AVDL 的持股。Chilton Capital Management LLC 在第一季度购入了价值 51000 美元的 Avadel 制药股票。BNP Paribas Financial Markets 在第一季度增持了 Avadel 制药的股票，持股增长了 60.5%。BNP Paribas Financial Markets 现在拥有 4469 股该公司股票，价值 75000 美元，比上一季度增持 1685 股。Quarry LP 在第四季度购入了价值约 12 万美元的 Avadel 制药股票。Claro Advisors LLC 在第一季度购入了价值约 17.2 万美元的 Avadel 制药股票。最后，中国通用资产管理有限公司在第四季度将其对 Avadel 制药的持仓增加了 349.4%。中国通用资产管理有限公司现在拥有 10327 股该公司股票，价值 146000 美元，在该时期内增持了 8029 股。机构投资者拥有该公司股票的 69.19%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的观点</h2>
</div><p>A number of research firms recently weighed in on AVDL. Rodman &amp; Renshaw initiated coverage on shares of Avadel Pharmaceuticals in a research report on Wednesday, June 12th. They set a &#34;buy&#34; rating and a $27.00 price target on the stock. Craig Hallum boosted their target price on Avadel Pharmaceuticals from $22.00 to $23.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, May 9th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and set a $22.00 price target on shares of Avadel Pharmaceuticals in a research report on Wednesday, May 8th. HC Wainwright lifted their price target on Avadel Pharmaceuticals from $25.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, May 9th. Finally, Oppenheimer upped their price objective on Avadel Pharmaceuticals from $27.00 to $29.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, March 5th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Avadel Pharmaceuticals currently has an average rating of &#34;Buy&#34; and a consensus price target of $24.57.</p>
<div class="lb-trans"><p>一些研究公司最近对 AVDL 发表了意见。Rodman \u0026 Renshaw 在 6 月 12 日星期三的研究报告中对 Avadel 制药的股票进行了覆盖。他们给出了一项&#34;买入&#34;评级，并将股票的目标价定为 27.00 美元。Craig Hallum 将 Avadel 制药的目标价从 22.00 美元上调至 23.00 美元，并在 5 月 9 日星期四的研究报告中给予该股票&#34;买入&#34;评级。Needham \u0026 Company LLC 在 5 月 8 日星期三的研究报告中重申了对 Avadel 制药的&#34;买入&#34;评级，并将目标价定为 22.00 美元。HC Wainwright 将 Avadel 制药的目标价从 25.00 美元上调至 27.00 美元，并在 5 月 9 日星期四的报告中给予该股票&#34;买入&#34;评级。最后，Oppenheimer 将 Avadel 制药的目标价从 27.00 美元上调至 29.00 美元，并在 3 月 5 日星期二的研究报告中给予该公司&#34;表现优异&#34;评级。根据 MarketBeat.com 的数据，七位股票研究分析师对该股票给出了买入评级，Avadel 制药目前的平均评级为&#34;买入&#34;，共识目标价为 24.57 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Avadel Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Avadel 制药的最新股票报告</strong></p>
</div><h2>Avadel Pharmaceuticals Trading Down 1.7 %</h2>
<div class="lb-trans"><h2>Avadel 制药股价下跌 1.7%</h2>
</div><p>Avadel Pharmaceuticals stock opened at $14.06 on Monday. The business's 50 day simple moving average is $16.12 and its 200 day simple moving average is $15.43. Avadel Pharmaceuticals has a 12 month low of $9.50 and a 12 month high of $19.09. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -7.56 and a beta of 1.53.</p>
<div class="lb-trans"><p>周一，Avadel 制药股票开盘价为 14.06 美元。该公司的 50 天简单移动平均线为 16.12 美元，200 天简单移动平均线为 15.43 美元。Avadel 制药的 12 个月最低价为 9.50 美元，最高价为 19.09 美元。该公司的市值为 13.5 亿美元，市盈率为-7.56，贝塔系数为 1.53。</p>
</div><p>Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05). Avadel Pharmaceuticals had a negative net margin of 284.42% and a negative return on equity of 139.72%. The firm had revenue of $27.18 million for the quarter, compared to analysts' expectations of $25.89 million. During the same period in the prior year, the company earned ($0.48) EPS. The firm's quarterly revenue was up 2617.8% on a year-over-year basis. As a group, equities research analysts forecast that Avadel Pharmaceuticals will post -0.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Avadel 制药（NASDAQ:AVDL）于 5 月 8 日发布了季度财报。公司报告的每股收益为-0.30 美元，低于分析师预期的-0.25 美元。Avadel 制药的净利润率为-284.42%，净资产收益率为-139.72%。该季度公司的营收为 2718 万美元，超过分析师对 2589 万美元的预期。与去年同期相比，公司的季度营收同比增长 2617.8%。作为一个群体，股票研究分析师预计，Avadel 制药本财年的每股收益将为-0.58 美元。</p>
</div><h2>About Avadel Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Avadel 制药（获取免费报告）</h2>
</div><p>Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.</p>
<div class="lb-trans"><p>Avadel 制药公司是一家在美国运营的生物制药公司。其主要产品候选药物是 LUMRYZ，一种盐酸奥沙巴汀的制剂，目前正在进行用于治疗成年人的过度日间嗜睡或猝倒的第 3 期临床试验。该公司以前被称为 Flamel Technologies SA，于 2017 年 1 月更名为 Avadel 制药公司。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Avadel Pharmaceuticals</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Palo Alto Networks Stock Gains AI-Powered Cybersecurity Solutions</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票比 Avadel 制药更好</li>
<li>3 家可以帮助抵御通货膨胀的杂货股</li>
<li>分析师升级的 3 只股票：家得宝、美国钢铁、美国铝业</li>
<li>内部人士出售解释：它能指导您的投资选择吗？</li>
<li>NVIDIA 和 TSM 股票：半导体行业的势头是否减缓？</li>
<li>什么是标准普尔 500 指数及其与其他指数的区别</li>
<li>Palo Alto Networks 股票获得基于人工智能的网络安全解决方案的增益</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><p>→ Jeff Bezos &amp; 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ Jeff Bezos 和 48 名国会议员正在购买一个行业...（来自 InvestorPlace）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTE1" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8515&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Avadel Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 Avadel 制药？</h2>
</div><p>Before you consider Avadel Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Avadel 制药之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在应该购买的股票...而 Avadel 制药不在这份名单上。</p>
</div><p>While Avadel Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Avadel 制药目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票是更好的选择。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Avadel 制药公司（纳斯达克：AVDL）的空头头寸增长了 11.1%